Pre-Submission Optimization for EU/UK: How US Biotechs Can Adapt FDA Packages Efficiently

1. Start by deciding what can be reused, adapted, or rebuilt

Before working on templates or formats, teams should review the target product profile and assess how this aligns with EU and UK precedents and the regulatory environment for the intended treatment. This exercise will provide a critical review of the data and assess if it aligns with local requirements or guidelines, whilst also inputting into a reuse map for the dossier.

The reuse map will define what can be reused, what dossier components must be adapted, and what needs to be rebuilt, since many EU and UK requirements sit at the regional and procedural level rather than in the core science. A practical approach is to create a reuse map covering four main areas:

• Regional administrative content in Module 1, which must usually be rebuilt,
• Expert overview or summaries in Module 2, which often require updates to meet EU or UK requirements,
• CMC and Quality information in Module 3, which are transferable but often require reframing around EU expectations for control strategy and readiness,
• Core scientific modules (Modules 4 to 5), which generally follow ICH standards and offer high reuse potential.

This reuse map becomes a pre-submission blueprint, which can be combined with execution-related materials such as response tracking and correspondence planning, which are not documents in themselves but determine timeline control and will help teams allocate effort realistically and preventing late-stage discovery of regional gaps.

2. Treat EU and UK submissions as parallel conversion tracks

Although EU and UK technical expectations are similar, their procedural frameworks differ and must be managed separately. In the EU, marketing authorisation applications for innovative products are often handled through the Centralised Procedure and managed by the European Medicines Agency (EMA). This process results in a single marketing authorization valid throughout all EU Member States, however for some products National applications to one or several EU Member States can also be undertaken. In the UK, marketing authorisation applications are submitted to and assessed by the Medicines and Healthcare Products Regulatory Agency (MHRA), and although there remains alignment EU dossier requirements, specific procedural and documentation requirements should be planned for.

An efficient model is therefore to build a shared technical core while running two regional conversion tracks for Module 1 and procedural artefacts, rather than attempting to manage both regions as a single pathway.

3. Adapt the regulatory narrative, not only the files

One of the most underestimated tasks in EU and UK preparation is narrative alignment. FDA-oriented dossiers often reflect US terminology, assumptions, and interaction models, while European reviewers expect different framing, particularly around quality, risk management, and operational governance.

Pre-submission optimization should therefore include checks on regulatory logic, demonstrating why the chosen pathway is appropriate, quality readiness, showing that manufacturing and control strategies are credible, and operational coherence, ensuring that responsibilities and handoffs are clearly defined. Targeted gap assessments are valuable in this context, not as formal compliance exercises, but as tools to guide efficient conversion.

4. Plan from the start for a full rebuild of Module 1

Administrative and procedural content is often the largest hidden source of delay. In the EU, structured electronic forms and eSubmission standards apply, supported by detailed EMA guidance. In the UK, eCTD submissions follow similar technical standards but include UK-specific Module 1 requirements.

Effective pre-submission planning means recognizing early that Module 1 is a build activity, defining ownership, sources of information, and quality control processes, rather than attempting incremental reuse through copying and modification.

5. Prepare for system and process requirements in advance

Both EU and UK review processes impose operational prerequisites that can disrupt timelines if left too late. EMA systems require correct sponsor registration, entity configuration, and user access, while MHRA have similar, but less demanding system registration requirements.

A robust pre-submission package should therefore include an execution plan covering ownership of the above aspects, response governance, version control, and escalation pathways, ensuring that procedural obstacles do not become critical path delays.

In summary

An effective conversion approach for late-stage biotechs typically includes defining target procedures and scope, building the reuse map across technical modules, running focused gap assessments to ensure content, narratives and summaries are aligned with EU and UK expectations and the sponsor's proposed position. Preparing EU and UK system access early and mapping out ownership and response governance processes before submission.

This workflow keeps the effort proportional, maximizing reuse where appropriate while avoiding late-stage rework driven by regional non-compliance.

References

• EMA. eSubmission and Electronic Application Forms

Scale Your Biotech from Lab to Market

Dedicated regulatory, CMC, clinical, and quality support for emerging biotech companies developing novel therapies.